Could a psychedelic trip whose most intense effects fade within about 20 minutes help people with depression? In this episode, Dr Alex is joined by Dr Anya Borissova, an academic psychiatry registrar, to discuss a clinical trial of 5-MeO-DMT. Researchers gave people with treatment-resistant depression a single dose of an experimental nasal spray and measured their symptoms 29 days later. They talk through what the trial found, why a shorter psychedelic experience might make this kind of treatment easier to deliver, and why it’s so hard to design a convincing placebo for psychedelics studies. They also discuss some of the more surprising findings of the study. What do you think matters most in psychedelic treatment? Let us know in the YouTube comments. Link to Study: Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression https://jamanetwork.com/journals/jama/article-abstract/2855796 Presented by Dr. Alex Curmi. Dr. Alex is a consultant psychiatrist and a UKCP registered psychotherapist. Get in touch: https://alexcurmitherapy.com/contact/ Check out The Thinking Mind Substack: https://thinkingmindblog.substack.com/ Speaking inquiries: https://alexcurmitherapy.com/speaking/ Coaching: https://alexcurmitherapy.com/practice/ Alex is not currently taking on new psychotherapy clients, if you are interested in working with Alex for self-development coaching, you can email - alexcurmitherapy@gmail.com with "Coaching" in the subject line. Give feedback here - thinkingmindpodcast@gmail.com Follow us here: Twitter @thinkingmindpod Instagram @thinkingmindpodcast
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_00The core thing that's really different with this study compared to lots of the other psychedelic treatment studies is that rather than getting people in for a full day, sort of four to six hour or twelve hour like you would with psilocybin or LSD, you've got people in and out in the space of a couple of hours. And the psychedelic experience itself is really quite short-lived, sort of, you know, peak effects dropping sort of within 20 minutes. Why is this exciting? It means that if it works, it's way more translatable into clinical practice.
SPEAKER_00So it's way easier to actually fit this into a normal natural clinical setting that currently exists.
SPEAKER_01Welcome back, everyone. Today we're going to be talking again about psychedelics and could they be useful in treating depression? And we're going to talk about that through the lens of this cool new study, which I'm going to be discussing with my co-host, Dr. Anya Borasova, who is an academic psychiatry trainee. What that means, the academic part, is that she spends a lot of time thinking about research. So she's always the best person to discuss specific studies like this. Dr. Anya, thank you so much for joining me today.
SPEAKER_00Pleasure. Hello, Alex.
SPEAKER_01So what what is the study that you're going to be talking to us about? And why did you specifically want to bring this study to our attention?
SPEAKER_00So, as you've said, Alex, we talk about psychedelics a reasonable amount on this podcast. And one of the reasons is that they are a burgeoning field when it comes to the treatment of mental illnesses that are difficult to treat with more traditional treatments. And so this is a study that seeks to give us a bit of a clue as to whether a new and different psychedelic to what's been mostly tested before might have effects in treatment-resistant depression, as in depression that hasn't responded to lots of other treatments.
SPEAKER_00So basically, could we have a new treatment on the horizon? So in this study, they're looking at a synthetic version of 5MEO DMT. Now, it's something that people may have heard of, but I think more commonly people have heard of DMT, which is the main active ingredient in ayahuasca. I think ayahuasca is probably kind of in a lot of people's minds. And so when people hear of 5MEO DMT, often there's the assumption that it's the same thing. It's not. It's despite sounding quite similar and having some similarities in chemical structure, it's a very different drug.
SPEAKER_00So the it's a drug that's not been tested as much for treatment-resistant depression. Um now this is the second uh randomized controlled trial of this drug in treatment-resistant depression. The first one came out last March, I believe, but it kind of bypassed me because I just had a baby. So apologies. But the reason why I think it's great to talk about this one is that one, it's the second paper kind of with a similar drug, but done by a different drug company.
SPEAKER_00And it gives us an idea about what we can expect in terms of treatment effects with a fast-acting psychedelic drug. So I think the core thing that's really different with this study compared to lots of the other psychedelic treatment studies is that rather than getting people in for a full-day sort of four to six hour or 12-hour psychedelic experience, like you would with psilocybin or LSD, you've got people in and out in the space of a couple of hours.
SPEAKER_00And the psychedelic experience itself is really quite short-lived, sort of, you know, peak effects dropping sort of within 20 minutes. Why is this exciting? It means that if it works, it's way more translatable into clinical practice. So it's way easier to actually fit this into a normal natural clinical setting that currently exists. So
SPEAKER_01Right, that's awesome. So it really removes one of the big obstacles, which is this, you know, huge amount of time. You take psilocybin mushrooms, and you have to sit with a patient for like six to eight hours. They take NSD, it's like 12 hours, whereas this is in and out for two hours.
SPEAKER_00Right, exactly. And it's quite a different drug in terms of the experience that people get as well. So the one of the things that I think is interesting and, you know, maybe maybe part of our discussion today is that it's a drug that's not associated with much in the way of visual effects. Uh it's a drug that's known, I guess, colloquially as being one of the most intense psychedelics or the most intense psychedelic. Now, you know, that's take that with a pinch of salt, because obviously it's always a question of dose, and also there's individual effects.
SPEAKER_00But what people tend to describe with this drug is sort of a very fast onset. If they've got on the on the higher doses, people really lose their sense of self. So this sort of ego dissolution type effects. It can be quite physical, so people can become kind of really shaky, potentially experiencing things like vomiting, known again colloquially as purging. People uh describe sometimes having a white light that they can see, and this will contrast with what people might know of DMT, where people sort of meet entities or aliens and things like this.
SPEAKER_00That doesn't really tend to get reported with this drug. But it gives people a really sort of intense experience, often kind of an emotionally intense experience, sometimes described as quite cathartic. Range of experiences that different people have, but that's to give people an idea of what participants in this study might have experienced.
SPEAKER_01And how can how does someone take this drug?
SPEAKER_00In this study, what they've done is they've developed an intranasal preparation. So what that means is they've got a basically a nasal spray. So, you
unknownknow,
SPEAKER_00if you've taken Pseudafed or you've taken other decongestions when you've got a cold, kind of that kind of thing. So you you you know, you've got a little spray bottle, the research team sprayed up your nose, and off you go. So no needles, no cannulas, no blood tests. So again, potentially a slightly easier administration than other drugs that we've also talked about for treatment-resistant depression, like ketamine, which sometimes are administered intravenously. So there again, an intranasal version exists.
SPEAKER_01And to get to a study like this, would they have already had to uh have established that the drug is essentially safe, like physiologically safe, not toxic, etc.?
SPEAKER_00Yeah, and really good point, because actually five amio DMT is one of those that has more, I guess, physiological or bodily concerns than some of the other drugs. So absolutely. So there's there was a big study that was actually run at King's College London, uh, where you and I both worked and trained, where they tested the drug on healthy volunteers, so people who have no mental illness, they tested out a range of different doses to check that the drug was safe, it's safe, safe there.
SPEAKER_00And even before getting to that stage, the drug would have undergone loads of testing, you know, most likely in animals and and sort of smaller groups of people as well.
SPEAKER_01Okay, cool. So how did they set up the study itself?
SPEAKER_00So I think the one of the, and this is one of the big strengths, is that they had a few different sites where the study was being run out of. So we're looking at sort of a mixture of Europe and USA, which is useful because that tells you that potentially the results are going to be applicable to different settings. But I think the other thing that's important is that it's not so many sites that you've kind of really diluted the experience. So each site was still recruiting could have a reasonable number of participants to mean that hopefully they were all doing similar things.
SPEAKER_00They had three different groups. So they had one group uh receiving a really, really minuscule dose of the drug, a group receiving it, so it was 0.3 milligrams, a group receiving a more medium dose, which was eight milligrams, and then another group receiving what they thought was going to be the optimal treatment dose of 12 milligrams. And they got people in initially for psychological preparation sessions. So this involved really quite standard in psychedelic research because you're giving people a drug that's going to give them such a sort of intense psychological experience.
SPEAKER_00You've got to get people prepared for that. And what that looked like for them was building rapport with the people who are going to be supporting you during the experience, but also teaching you things like kind of grounding techniques, meditation techniques, and deciding what kind of support they would want in the session if they felt really distressed or uncomfortable. So, as in making a decision before receiving the drug about if they would want to be touched, uh, if they would want to, or if actually they refused, you know, they just want to be grounded sort of with words.
SPEAKER_00So everyone got that psychological support, which is really important because as we know with mental illness, actually psychological support is a can be a core part of treatment. So what we don't want to see is that people are just getting better because that's they're getting that treatment as well.
SPEAKER_01So so these were all people experiencing treatment-resistant depression, is that right?
SPEAKER_00Yes, exactly. Um, so all people with treatment-resistant depression. Now, you've got to be uh what's the word? You've got to be curious about what studies mean when they say treatment-resistant depression, because it's sort of a a kind of a defined term, but there's a lot of variability in it. So, you know, the most basic. So my
SPEAKER_01my understanding is it's like depression that hasn't responded responded to at least two antidepressant treatments. That's that would be my like box standard answer.
SPEAKER_00Exactly. Exactly. But imagine, and you know, people who uh know anyone with depression probably can also, you know, they'll know that that encompasses a huge range of people, you know, and someone who's not responded, someone who responds to their third treatment is very different from someone who hasn't responded to their you know, fifth or sixth treatment. Uh so in this particular study, they were looking at people who either had had just one episode of depression or who had had multiple episodes of depression. If it was just one episode of depression, they had quite a concrete amount of time that they accepted.
SPEAKER_00So it had to have lasted no longer than two years. They accepted people, I think, who had not tried more than five treatments. So they did sort of have an upper limit there. And they didn't m include psychological treatments as some of those attempted treatments, which I think is an interesting point. So some studies do count psychological therapy as a treatment trial, arguably appropriately so. But it's again, it's it's not unusual not to count it. So it's it's it's a call that people make.
SPEAKER_00They were people who didn't have a huge amount of suicidal thoughts, so they were allowed to have experienced suicidal thoughts, but sort of not in the moment of being recruited for the study, or at least not with any intent to act on those thoughts. So that's again a fairly. Exactly. Exactly. And they they were also people who couldn't have tried and not responded to the more uh latter stage treatments that we have available in depression, so things like ketamine and electroconvulsive therapy.
SPEAKER_01Right.
SPEAKER_00So again, not not a really weird choice for the study team to make, but it just means that if you're thinking about the most severe end of treatment-resistant depression, these weren't the people being recruited for the study.
SPEAKER_01How many doses of five MEO DMT did the child participants receive?
SPEAKER_00So just the one. Just one.
SPEAKER_01Okay, just one. Yeah. And how did they follow up their response? How did they check, you know, how their depression symptoms responded to the treatment?
SPEAKER_00So again, I think this is a really nice bit of the study. So their primary outcome, so the thing that they said, you know, before running the study that was going to sort of be their headline news, was that they were interested in the people's response at day 29, which is actually a lot of studies will, you know, look, will report the results at either the sort of first 48 hours or the first week within the psychedelic world. So looking at the end of effectively the first month or four weeks is actually quite. 29 days
SPEAKER_01after they received the dose.
SPEAKER_00Exactly. Is I think clinically quite a nice choice because as a clinician, you're not you don't care that much what happens two days after someone gets a treatment. What you really want to know is is this treatment going to keep my patient better long term? In total, they followed people up over eight weeks, and they they followed people up at regular intervals over those eight weeks.
SPEAKER_01Okay, cool. And I'm assuming they they weren't getting sometimes you can get like a form of therapy while you're having the psychedelic experience.
SPEAKER_00And I'm
SPEAKER_01assuming they didn't have that because it's so short, it's like a 20-minute experience. Is that is that true?
SPEAKER_00Yeah, exactly. So the um again within the psychedelic literature, it's a fairly standard procedure that they followed. So they people came in for three preparation sessions before the psychedelic experience. They were supported by a trained uh facilitator during the psychedelic experience, but no active therapy was being done during the experience. I mean, it's often it with drugs like this, it's just too intense to really do anything. And then they had, I think, three integration sessions after the psychedelic experience.
SPEAKER_01Okay. Um
SPEAKER_00so those
SPEAKER_01integration sessions for people who don't know, it's to help them make sense of the experience that they would have had and make some use of it psychologically.
SPEAKER_00Yeah. And very, you know, they were uh very clear that what people were receiving was psychological support. They're not calling it psychological therapy. Uh, you know, that could probably be the topic of an entire podcast itself in terms of, well, what is the difference between psychological support and formal therapy? But it's it's an important distinction that drug companies are making in this field of research because their end goal is to get a drug licensed and you can't really get a therapy licensed in the same way.
SPEAKER_00And you want to show that it's they well, they want to convince people that it's just the drug doing the work ideally so that things don't the waters don't get muddied by saying that you also need a particular kind of therapy
SPEAKER_01when
SPEAKER_00you're administering this drug as a clinician.
SPEAKER_01Okay, cool. So now that we have an understanding of what happened, what what did the results show?
SPEAKER_00The results were interesting. Um so the results, I mean, broad headline in simple terms, the results were positive, unsurprisingly. That's probably one of the reasons that this paper's made made noise. I think the key thing that we didn't mention in the setup, but relevant to the results, is that they had quite good numbers of participants in each group. So especially for sort of a kind of first, one of the first few trials in this, when you compare it to the first psilocybin trials, you know, who often had like 20, 30 participants at the most, they had almost, I think, 180 participants, or sort of around the around the 180, they had about 70, 70-ish participants in their high dose group, 70-ish participants in their placebo low dose
SPEAKER_01group,
SPEAKER_00and then just under 50 participants in their middle dose group. So like really not bad numbers in terms of in terms of an early trial, and like a you know, these things are so expensive to run. So, like uh an uh, I guess a sign of the investment that the company were making in running.
SPEAKER_01And then what were the differences between the groups?
SPEAKER_00So their low-dose group, unsurprisingly, didn't have much um of a treatment response, but there was still a placebo response, which is what you would hope to see to sort of show that the your use of having a placebo group has worked. Because what you're trying, because you in all treatments, especially mental health treatments, people will just improve in their symptoms by virtue of being in the study. They then found that for their uh 8 milligram and 12 milligram dose group, there were fairly similar improvements.
SPEAKER_00On some of their outcomes, the 8 milligram dose group actually did better than the 12 milligram dose group. So, whereas they thought that their 12 milligram dose as the higher dose was going to be the most effective one, if anything would be effective, actually balancing the treatment, the kind of positive treatment effects, but also the negative side effects, the 8 milligram dose group did better. What does better look like? It was roughly sort of five to six points on a symptom scale, um, which isn't doesn't sound uh amazing when you say it like that, you know, given that these symptom scales, people starting out in the study would have had 30-ish points uh out of you know 40 to 50.
SPEAKER_00So a drop of five to six, you know, they've still got significant symptoms on average. But what that what that five to six point average doesn't tell you about is the individual response. So, you know, some people would have had a much greater response, say 10, you know, 10, 15, 20 points. Some people would have had a much smaller response. Again, a completely normal part of how clinical research happens.
SPEAKER_01So some individuals in the study may have had their depression actually resolved, you know, more or less completely or like below what you would consider to be like diagnosable depression. Some might have had more modest improvement, some might have had no improvement.
SPEAKER_00Exactly. And there's there's sort of the numbers of people who had went into like a remission, so that they, according to standardized definitions, wouldn't be diagnosable with depression anymore, was somewhere in the region of 25 to 30 percent in the in the very in the in the higher dose groups, so in the 8 and 12 milligram dose groups. But it was still in the region of sort of 10 to 15 percent in the low dose placebo group. So
SPEAKER_01the
SPEAKER_00actual difference, uh so actually only about you know 15 to 20-ish percent of people uh had a full remission, which is good, but not necessarily as good as some of the other both kind of psychedelic drugs that we see and ketamine drugs that we see working in in treatment-resistant depression. There, the responses can be quoted as being a bit higher. But, you know, again, we take that with a pinch of salt.
SPEAKER_01So, I mean, a pretty good result considering they only took one dose of a drug, which gives a very short experience and they were being followed up 30 days on, presumably with minimal, you know, physical side effects other than during the experiment itself, were there any kind of longer lasting physical side effects?
SPEAKER_00No, so it seems to have been well tolerated. So the things that you worry about most with 5MEO DMT is that it its effects on the heart. So it raises your blood pressure, it raises your heart rate. Uh so if you're someone who has any heart problems, you're probably not taking part in this study. But um, you know, things happen that you may not have foreseen, or people without any existing problems develop something new. Actually, they they didn't report any serious, um, serious effects. The majority of the effects were short-lived around the time of the dosing.
SPEAKER_00You know, people experience discomfort from the administration, like a burning sensation in their nose or throat. People have nausea, vomiting, uh, people get headaches. These were higher in the higher dose group, but they weren't they sort of they they seem to resolve and they didn't lead to they didn't lead to huge numbers of people dropping out from the study. The other thing that you worry about, not just physical side effects, is the emergence of uh suicidal behavior. So it's definitely been an issue that has arisen with the Silas Iban trials, whereby most commonly people in the placebo group, so people getting a non-effectively like not experiencing an intense psychedelic experience, uh know that they've had a placebo.
SPEAKER_00We presume that there's a fair bit of disappointment associated with that, or even people who have had the psychedelic experience but haven't noticed an improvement in the symptoms. Again, we presume a fair amount of disappointment associated with that. And you see a small, but because it's such a serious thing, a small but significant number of people who have an increase in their suicidal thoughts, or even very rarely, but again, very seriously, increase in suicidal behavior.
SPEAKER_01Yeah. And this didn't happen in this study as far as we know.
SPEAKER_00Again, there's a so so there was a little bit of a signal. Um, given the small numbers, it's hard to know how that will translate if they do a study with, you know, a thousand participants. But we did we didn't see any suicidal acts or suicidal uh, you know, people people doing something to hurt themselves, but we saw that there was some increase in thoughts that people had about feeling that life wasn't worth living. So
SPEAKER_01And was that clearly in one group over the other, or was it like were there some uh individuals in every group who had uh experienced some suicidal thoughts?
SPEAKER_00There were some individuals in every group. Numerically, it looked a little bit higher in the in the very low dose group, but it it's such small numbers that I think it's it wouldn't be accurate to draw firm conclusions from that, but it is an important thing to keep an eye on.
SPEAKER_01Yeah, absolutely. Is there anything else you want to mention in terms of results before we talk about like strengths and limitations of the study?
SPEAKER_00I think an interesting thing, especially within the psychedelic world, is people who really want to know you know, what is it that about these drugs that is a treatment effect? And And with psilocybin, there's been so there's been some studies that have shown that what seems to be a really important thing is the mist level the degree of mystical experience. Exactly, yeah, yeah, yeah. So the degree, you know, how and these experiences are are often quite hard for people to put into words, but there are, again, there's a mystical experience questionnaire that tries to measure the level of the mystical experience.
SPEAKER_00And in this study, uh the level of mystical experience that people had didn't seem to be associated with their level of treat treatment response.
SPEAKER_01Which
SPEAKER_00is different, right? So
SPEAKER_01having a different from other studies
SPEAKER_00Exactly. So having a stronger mystical experience didn't seem to mean that you had a better response in your depression symptoms, or having less of a meaningful experience again, didn't seem to translate to not having improvements in your depression. Is that going to be a feature of just this drug? It's definitely too soon to tell. But it's an interesting point, especially for camps of people who really want to create a psychedelic with no psychedelic effects, and who they believe that there's just something about the drug itself, what it does in the brain on a molecular level that's responsible for the treatment effect, and that it is nothing to do with the experience that you have, you know, the uh loss of self or the kind
SPEAKER_01of
SPEAKER_00broader view of yourself, or that you know, people say, nah, that's nothing to do with it. So this gives this gives people in that camp probably something to chew on excitedly.
SPEAKER_01Think about in terms of the strength of the study. So you mentioned, you know, it was a multi-site trial, which gives it some more credence, perhaps towards replicability. You mentioned that obviously we've got three groups, and I think it's really cool to have as the control arm the patients receiving a very tiny dose as opposed to receiving nothing, because that's a really clever way of blinding people so people don't really know what they're getting. Um, and you mentioned that there was like a decent number of people involved in the study.
SPEAKER_01Is there anything else you want to point out in terms of why what makes the study like a good, reliable piece of science?
SPEAKER_00I think the other things are, I mean, and they're not exciting things, but they're things like having your protocol published in advance. So sort of saying loud and clear to the world, you know, these are the scales that we're going to look at. And as you've as we saw in this study, you know, they had slightly different patterns of results on some of the different scales. Uh so for example, the self-report scale actually didn't show as much of a as much of a response as the clinician independent rater measured
SPEAKER_01scale.
SPEAKER_00It it could potentially be very easy for people to initially say we're going to look at the self-report scale and then have a look at the results and change it to the clinician-rated scale.
SPEAKER_01Right.
SPEAKER_00They so protocols were published in advance, kind of everything laid out exactly what they were doing. Those are important things. Otherwise, I think we've covered sort of the the headline, headline strengths.
SPEAKER_01And what do you think are the main limitations of the study?
SPEAKER_00This is always the you know, this is always the saddest bit because you can always you can always pull out limitations. And it is, it's a shame because obviously everyone sets out uh well, we can be cynical and say people set out just to make money, but I think probably most people set out just to do good science.
SPEAKER_01And
SPEAKER_00you can never do science that is as good as you would want to in an ideal world. So, you know, I think issues that you just can't get away from is that this was funded by a drug company, it was, you know, run completely by a drug company, and with the best will in the world, uh, we just have to uh note that and uh look for at some point independent replication. But realistically, these things are expensive to run, you know, purely academic, non-drug company settings, they're not going to have the money to run them.
SPEAKER_00So we have to work in tandem with drug companies to get this kind of research done to get new treatment options for people. The other limitations, I think, are in the types of people that they recruited. So, as is really common in psychedelic studies, the demographics were really not very varied. So we're looking at mostly white, ethnically, ethnically white participants. And we know that different people uh of different ethnicities have different experiences in life, they're exposed to different societal pressures.
SPEAKER_01And they may indeed respond differently to different treatments. And they
SPEAKER_00may indeed respond differently. And we've seen that you know with drugs like clozapine, commonly used in psychiatry. We've seen that there, you know, very much can be differences in the ways that people's bodies use the drug. So that's what we want to see in the future. We really want to see more diverse um samples. And I
SPEAKER_01guess as you already said, it's it's uh generally a lower risk population. So maybe people who aren't as acutely or severely depressed as people we might see in the general population.
SPEAKER_00Yeah, exactly. So I think you know, they the their symptom scores were of a high severity. But again, in terms of like the treatment histories that these people had, they're they're not the most they're not the most unwell people. And as ever in a clinical trial, you've got to have a certain level of motivation and a certain level of wellness to actually be able to participate, even volunteer, get through the screening process. So again, we're gonna need more time before we can say that this is something that's clinically that's going to be clinically very helpful to us.
SPEAKER_01What do you think are the implications of the study? So given that the study exists, what do we as a scientific community need to do next?
SPEAKER_00So I think in terms of right now implications, I think it's to say, let's let's look at this drug more because we've got two well-conducted with reasonable numbers, uh randomized controlled trials that uh show us that there does seem to be a treatment effect of this short-acting psychedelic drug. I think the question, the you know, the million-dollar question in psychedelic research is how do you blind better? You know, so you've said, Alex, that uh uh a strength of this study is that they used a low dose of the drug as their placebo group.
SPEAKER_00And it's a strength in a sense because it it means you can tell everyone going into the study that they're getting the drug. And so you sort of up until the moment that people receive the drug, everyone's expectation is kind of the same. But these drugs have such strong effects that unfortunately, the instant that you receive the drug, it becomes pretty clear what uh whether you've received like a full treatment dose or not.
SPEAKER_01I think most of the time that's true, but I heard from someone who participated in a silus hybin trial. They were a doctor in a silus hybin trial, and they there was a participant in the trial who, you know, by all appearances had a full psychedelic experience only to turn out to not have been given the drug at all, at any dose, was given a total uh 100% placebo. So I do agree with you. I think I'm sure that's the case most of the time, but our brains are very powerful and very powerful things can happen.
SPEAKER_00Our brains are very powerful. Uh no, agreed completely. As in, I think it's it's not to say that we there's no point even trying to have a placebo group, but you know, so they measured blind the level of blinding in this study, and actually people mostly knew what they were. Mostly
SPEAKER_01were able to guess.
SPEAKER_00Exactly.
SPEAKER_01Which is understandable.
SPEAKER_00Yeah. And you know, so they they tried to get around that by using independent raters, uh, so people who weren't in the room at the time of the experience, people who were sort of video speaking to the person at day 29, rating their symptom scores. So they they put in the things that are available to put in. But again, if we could come up with a really good placebo that gives people as much, you know, that gives people a really strange experience, but has no antidepressant effects, if we could find that as a placebo, that would be a really big win for this research field.
SPEAKER_00And I think I think that's something that we have no idea about at the moment, but is is sort of a future, a future direction. Or like what as we mentioned before, a future direction being developing these drugs so that they don't have any strong effects and that you somehow are just acting on the same same parts of the brain
SPEAKER_01as these
SPEAKER_00drugs, but without any
SPEAKER_01psychedelic effect at all.
SPEAKER_00Yeah.
SPEAKER_01Maybe that'd be like the with psychedelic and without psychedelic versions, and people can have the different one according to their preference. Would you like to have a mystical experience? I'm sure some people would. Some people are like, no, just give me the drug by itself, please.
SPEAKER_00Exactly. No, absolutely. And you know, that's a big that's a big thing in the field as well, is patient preferences gonna vary, you know. So because because some people who are saying who are a huge proponent of the mystical experience, I have to face to the fact that yes, some patients they just want to, they just want to sort of have the pill, not feel a huge amount, but feel better in terms of their illness. So yeah, I mean that would be great to have either option.
SPEAKER_01So the so the thing I'm taking away from the study, and as I mentioned to you offline, I didn't read the study, so I'm relying entirely on your testimony here today. And the thing I'm taking away is another potential tool in the arsenal. You know, when I was training, doing my training, the big concern was we just don't have enough treatments. You know, we have treatments which some people respond to, but not everyone. And now psychedelics are opening up as a potentially really valuable source of new interventions, and potentially within that 5 MeO DMT, another potentially useful treatment for depression, potentially, I suppose, other mental health conditions as well.
SPEAKER_01But that's a question that remains to be answered. Is that is that more or less what you're taking away?
SPEAKER_00I think I would, as ever, be boring and temper the degree of enthusiasm to make it a a potential with a very big P in that, you know, there's something like two, three hundred people who've who've received this five OMEO DMT in the in the scheme of clinical practice that's tiny. And this is like a yeah, this might be an this this is an avenue that's worth exploring further. And given the effects that we see with the other groups, with the other drugs in the same group, the other psychedelic drugs, you know, probably we can assume that there is going to be some treatment effect.
SPEAKER_00But uh we, you know, I think a a really key question that hopefully researchers will get to is who, you know, which patients are these group are these drugs actually useful for? Because as we mentioned right at the start, you know, you've got a range of treatment responses. And so how do you pick the people who are going to have that, you know, 12, 20 point treatment response to receive this treatment?
SPEAKER_01Which, in my view, has always been the biggest problem in psychiatry in general. It's a problem with antidepressants, mood stabilizers, antipsychotics, psychedelics, you'll always have people who respond really well, people who don't, people who can't tolerate even ADHD medication. And I feel like if we can figure out somehow, maybe through a better understanding of genetics or whatever it happens to be, if we can just under have a way of predicting who's going to be responding to what kind of treatment, that would be, that would make psychiatry so much more effective, I think.
SPEAKER_00100%. Couldn't agree more.
SPEAKER_01Thanks for listening, everyone. We hope you enjoyed this episode talking about a scientific study. We want to make more episodes like this when new, you know, interesting or relevant studies come out. Let us know what you think. Do comment on YouTube and of course do like, follow, and subscribe wherever you happen to be listening or watching. I wouldn't be doing my job if I didn't say that. Uh, Dr. Anya, thank you so much.
What happens when exposing wrongdoing becomes a form of entertainment? In this Thinking Films episode, Dr Alex explores Primetime, starring Robert Pattinson as Chris Hansen. The film raises uncomfortable questions about...
What happens when a psychiatrist has to put his own advice about facing fear into practice? In this episode, Dr Alex joins Dr Rosy Blunstone, a psychiatry and psychotherapy registrar, to discuss his experience of trying...
What can Netflix's Matthew Perry documentary teach us about the psychology of addiction? Matthew Perry achieved extraordinary fame and success, yet continued to struggle with addiction throughout his life. His story...
What happens when ordinary people are handed power over others, and how do they respond when that power is taken away? Do you have an inner monster waiting to be unleashed? In this episode, psychiatrist Dr Alex examines...
A major new government review has been published into mental health, ADHD and autism. Some headlines have framed it as a warning about ADHD and autism being overdiagnosed, but is that really what the report says? In...